Alkermes Flies As Q2 Results, Guidance Beat Estimates
Shares of biomedical issue Alkermes (ALKS) surged 5% Thursday when the company released blowout results for its September-ending quarter, its fiscal Q2, and issued better guidance than the Street had been expecting. The Dublin-headquartered company earned 17 cents per share in the quarter, 143% more than the year-earlier period and 6 cents more than analysts had estimated. Revenue rose 72% to $124 million, also beating estimates. The sales
Related Stocks:
Stock Market XML and JSON Data API provided by FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Press Release Service provided by PRConnect.
Stock quotes supplied by Six Financial
Postage Rates Bots go here